These data showed that vertical pathway inhibition strategies, such as combinations of KRAS G12C inhibitors with SHP2 inhibitors, may be effective in interrupting feedback reactivation of the RAS pathway following KRAS G12C inhibition and may represent a possible therapeutic approach for KRAS G12C cancers [82]. This evidence concerns the gene KRAS and cancer.